Title(s):
Professor of Oncology
Co-Director, Upper Aerodigestive Cancer Program
Director, Lung Cancer Therapeutics
Cancer Center Associate Director for Clinical Research
Director, Lung Cancer Therapeutics
Cancer Center Associate Director for Clinical Research
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Esophageal Cancer, Hematologic Oncology, Lung Cancer, Thoracic Cancer
Education and Experience
Training
- University of Chicago (Chicago IL)/ (1993)
Residencies
- University of Chicago (Chicago IL)/ Internal Medicine (1995)
Fellowships
- University of Chicago (Chicago IL)/ Hematology/Oncology (1998)
Certifications
- Medical Oncology, American Board of Internal Medicine (2008)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-502-0678
Appointment Phone: 410-955-8964
Fax: 410-502-0677
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Esophageal Cancer Program
- Sidney Kimmel Comprehensive Cancer Center
Bio
Physician Title
Co-Director, Upper Aerodigestive Cancer Program
Director, Lung Cancer Therapeutics
Cancer Center Associate Director for Clinical Research
Director, Lung Cancer Therapeutics
Cancer Center Associate Director for Clinical Research
Expertise
- Esophageal Cancer
- Hematologic Oncology
- Lung Cancer
- Thoracic Cancer
Research
Research and Publications
Research Summary
Dr. Rudin''s research is focused on the development and testing of novel treatments for lung cancer and other related diseases. The Rudin laboratory studies new approaches to treating lung cancer in preclinical models, and Dr. Rudin oversees many early phase clinical trials, evaluating these approaches in patients.
Journal Citations
Choong, N.W.; Mauer, A.M.; HOffman, P.C.; Rudin, C.M.; Winegarden, J.D.; Kozloff, M.; Wade, J.L.; Sciortino, D.F.; Szeto, L.; Vokes, E.E. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006;1(3):245-251.
Dritschilo, A.; Huang, C.H.; Rudin, C.M.; Marshall, J.; Collins, B.; Dul, J.L.; Zhang, C.; Kumar, D.; Gokhale, P.C.; Ahmad, A.; Ahmad, I.; Sherman, J.W.; Kasid, U.N. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res. 2006 Feb 15;12(4):1251-1259.
Ritch, P.; Rudin, C.M.; Bitran, J.D.; Edelman, M.J.; Makalinao, A.; Irwin, D.; Lilenbaum, R.; Peterson, P.; John, W.J. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2006 May;52(2):173-180.
Ross, H.J.; Hart, L.L.; Swanson, P.M.; Rarick, M.U.; Figlin, R.A.; Jacobs, A.D.; McCune, D.E.; Rosenberg, A.H.; Baron, A.D.; Grove, L.E.; Thorn, M.D.; Miller, D.M.; Drachman, J.G.; Rudin, C.M. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer. 2006 Oct;54(1):69-77.
Brace, J.L.; Lester, R.L.; Dickson, R.C.; Rudin, C.M. SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae. Genetics. 2007 Oct 22;175:65-76.
Hagan, C.R.; Rudin, C.M. DNA cleavage and Trp53 differentially affect SINE transcription. Genes Chromosomes Cancer. 2007 Mar;46(3):248-260.
Hann, C.L.; Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Apr;13(4):150-157.
Reddy, P.S.; Burroughs, K.D.; Hales, L.M.; Ganesh, S.; Jones, B.H.; Idamakanti, N.; Hay, C.; Li, S.S.; Skele, K.L.; Vasko, A.J.; Yang, J.; Watkins, D.N.; Rudin, C.M.; Hallenbeck, P.L. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007 Nov 7;99(21):1623-1633.
Choong, N.W.; Vokes, E.E.; Haraf, D.J.; Tothy, P.K.; Ferguson, M.K.; Kasza, K.; Rudin, C.M.; Hoffman, P.C.; Krauss, S.A.; Szeto, L.; Mauer, A.M. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan;3(1):59-67.
Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-2328.
Hann, C.L.; Rudin, C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008 Nov 30;22(13):1486-1492; discussion 1493-1486, 1498-1500, 1506.
Marur, S.; Rudin, C.M. Genetic alterations in head and neck squamous cell carcinogenesis. In: Rose, B.D., editor, UpToDate: Oncology. Wellesley, MA: UpToDate; 2008.
Marur, S.; Rudin, C.M. Chemoprevention in oral dysplasia. In: Rose, B.D., editor, UpToDate: Oncology. Wellesley, MA: UpToDate; 2008.
Rudin, C.M.; Hann, C.L.; Peacock, C.D.; Watkins, D.N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):315-322.
Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.
Rudin, C.M.; Salgia, R.; Wang, X.; Hodgson, L.D.; Masters, G.A.; Green, M.; Vokes, E.E. A Randomized phase II study of carboplatin and etoposide with or without oblimersen, antisense, bcl-2, for extensive stage small cell lung cancer. J Clin Oncol. 2008 Feb 20;26:870-876.
Daniel, V.C.; Marchionni, L.; Hierman, J.S.; Rhodes, J.T.; Devereux, W.L.; Rudin, C.M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C.D.; Watkins, D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009 Apr 15;69(8):3364-3373.
Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.
Hillion, J.; Wood, L.J.; Mukherjee, M.; Bhattacharya, R.; Di Cello, F.; Kowalski, J.; Elbahloul, O.; Segal, J.; Poirier, J.; Rudin, C.M.; Dhara, S.; Belton, A.; Joseph, B.; Zucker, S.; Resar, L.M. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009 Nov;7(11):1803-1812.
Hulleman, E.; Kazemier, K.M.; Holleman, A.; VanderWeele, D.J.; Rudin, C.M.; Broekhuis, M.J.; Evans, W.E.; Pieters, R.; Den Boer, M.L. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009 Feb 26;113(9):2014-2021.
Riely, G.J.; Rizvi, N.A.; Kris, M.G.; Milton, D.T.; Solit, D.B.; Rosen, N.; Senturk, E.; Azzoli, C.G.; Brahmer, J.R.; Sirotnak, F.M.; Seshan, V.E.; Fogle, M.; Ginsberg, M.; Miller, V.A.; Rudin, C.M. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jan 10;27(2):264-270.
Rudin, C.; Minna, J. Cancer stem cells. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1079-1081.
Rudin, C.M.; Avila-Tang, E.; Harris, C.C.; Herman, J.G.; Hirsch, F.R.; Pao, W.; Schwartz, A.G.; Vahakangas, K.H.; Samet, J.M. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009 Sep 15;15(18):5646-5661.
Rudin, C.M.; Avila-Tang, E.; Samet, J.M. Lung cancer in never smokers: a call to action. Clin Cancer Res. 2009 Sep 15;15(18):5622-5625.
Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; LoRusso, P.M.; Von Hoff, D.D.; de Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009 Sep 17;361(12):1173-1178.
Samet, J.M.; Avila-Tang, E.; Boffetta, P.; Hannan, L.M.; Olivo-Marston, S.; Thun, M.J.; Rudin, C.M. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009 Sep 15;15(18):5626-5645.
Schifferli, A.; von Vigier, R.O.; Fontana, M.; Sparta, G.; Schmid, H.; Bianchetti, M.G.; Rudin, C. Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003. European journal of pediatrics. 2009 Oct 15.
Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.
Yauch, R.L.; Dijkgraaf, G.J.; Alicke, B.; Januario, T.; Ahn, C.P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.A.; Tang, T.; Bazan, J.F.; Kan, Z.; Seshagiri, S.; Hann, C.L.; Gould, S.E.; Low, J.A.; Rudin, C.M.; de Sauvage, F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-574.
Burns, T.F.; Rudin, C.M. Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors. Oncology (Williston Park). 2010 Jan;24(1):48-49.
Kanarek, N.F.; Tsai, H.L.; Metzger-Gaud, S.; Damron, D.; Guseynova, A.; Klamerus, J.F.; Rudin, C.M. Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010 Dec;8(12):1343-1351.
Klamerus, J.F.; Bruinooge, S.S.; Ye, X.; Klamerus, M.L.; Damron, D.; Lansey, D.; Lowery, J.C.; Diaz, L.A., Jr.; Ford, J.G.; Kanarek, N.; Rudin, C.M. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res. 2010 Dec 15;16(24):5997-6003.
Paik, P.K.; Rudin, C.M.; Brown, A.; Rizvi, N.A.; Takebe, N.; Travis, W.; James, L.; Ginsberg, M.S.; Juergens, R.; Markus, S.; Tyson, L.; Subzwari, S.; Kris, M.G.; Krug, L.M. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-1085.
Paller, C.J.; Rudin, C.M. Youth has no age: cancer treatment for older Americans. Oncology (Williston Park). 2010 Nov 15;24(12):1114, 1118, 1120.
Peacock, C.D.; Rudin, C.M. Skin deep and deeper: multiple pathways in basal cell carcinogenesis. Cancer Prev Res (Phila). 2010 Oct;3(10):1213-1216.
Rudin, C.M. Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer Prev Res (Phila). 2010 Jan;3(1):1-3.
Rudin CM, Salgia R, Wang X, Hodgson L, Masters GA, Green M, Vokes EE. (2008) A randomized phase II study of carboplatin and etoposide with or without oblimersen, antisense bcl-2, for extensive stage small cell lung cancer. J Clin Oncol 26:870-6.
Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-2.
Hann CL, Daniel VC, Hierman J, Sugar E, Cope L, Lin M, Watkins DN, Rudin CM. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of Bcl-2, in small cell lung cancer. Cancer Res 68:2321-8.
Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, Evans WE, Pieters R, Den Boer ML. (2009) Inhibition of glycolysis modulates prednisolone resistance in pediatric acute lymphoblastic leukemia cells. Blood 113:2014-21.
Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. (2009) Randomized phase 2 study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with stage IIIB or IV non-small cell lung cancer. J Clin Oncol 27:264-70.
Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. (2009) Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14:119-20.
Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Dorsch M, Parmigiani G, Peacock C, Watkins DN. (2009) A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69:3364-73.
Rudin CM, Avila-Tang E, Samet JM. (2009) Lung cancer in never smokers: a call to action. Clin Cancer Res 15:5622-25.
Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Thun MJ, Rudin CM. (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15: 5626-45.
Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. (2009) Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 15:5646-611.
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. (2009). Inhibition of the Hedgehog pathway in advanced basal cell carcinoma. New Engl J Med 361:1164-72.
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff D, de Sauvage FJ, Low JA. (2009) Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. New Engl J Med 361:1173-8.
Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan A, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572-4.
Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, di Cello F, Kowalski J, Elbahloul O, Segal J, Poirier J, Rudin CM, Dhara S, Belton A, Joseph B, Zucker S, Resar LM. (2009) Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large cell lung cancer. Mol Cancer Ther 7:1803-12.
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg M, Markus S, Juergens R, Tyson L, Subzwari S, Kris MG, Krug LM. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol; (in press).
Dr. Rudin''s research is focused on the development and testing of novel treatments for lung cancer and other related diseases. The Rudin laboratory studies new approaches to treating lung cancer in preclinical models, and Dr. Rudin oversees many early phase clinical trials, evaluating these approaches in patients.
Journal Citations
Choong, N.W.; Mauer, A.M.; HOffman, P.C.; Rudin, C.M.; Winegarden, J.D.; Kozloff, M.; Wade, J.L.; Sciortino, D.F.; Szeto, L.; Vokes, E.E. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006;1(3):245-251.
Dritschilo, A.; Huang, C.H.; Rudin, C.M.; Marshall, J.; Collins, B.; Dul, J.L.; Zhang, C.; Kumar, D.; Gokhale, P.C.; Ahmad, A.; Ahmad, I.; Sherman, J.W.; Kasid, U.N. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res. 2006 Feb 15;12(4):1251-1259.
Ritch, P.; Rudin, C.M.; Bitran, J.D.; Edelman, M.J.; Makalinao, A.; Irwin, D.; Lilenbaum, R.; Peterson, P.; John, W.J. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2006 May;52(2):173-180.
Ross, H.J.; Hart, L.L.; Swanson, P.M.; Rarick, M.U.; Figlin, R.A.; Jacobs, A.D.; McCune, D.E.; Rosenberg, A.H.; Baron, A.D.; Grove, L.E.; Thorn, M.D.; Miller, D.M.; Drachman, J.G.; Rudin, C.M. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer. 2006 Oct;54(1):69-77.
Brace, J.L.; Lester, R.L.; Dickson, R.C.; Rudin, C.M. SVF1 regulates cell survival by affecting sphingolipid metabolism in Saccharomyces cerevisiae. Genetics. 2007 Oct 22;175:65-76.
Hagan, C.R.; Rudin, C.M. DNA cleavage and Trp53 differentially affect SINE transcription. Genes Chromosomes Cancer. 2007 Mar;46(3):248-260.
Hann, C.L.; Rudin, C.M. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends in molecular medicine. 2007 Apr;13(4):150-157.
Reddy, P.S.; Burroughs, K.D.; Hales, L.M.; Ganesh, S.; Jones, B.H.; Idamakanti, N.; Hay, C.; Li, S.S.; Skele, K.L.; Vasko, A.J.; Yang, J.; Watkins, D.N.; Rudin, C.M.; Hallenbeck, P.L. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007 Nov 7;99(21):1623-1633.
Choong, N.W.; Vokes, E.E.; Haraf, D.J.; Tothy, P.K.; Ferguson, M.K.; Kasza, K.; Rudin, C.M.; Hoffman, P.C.; Krauss, S.A.; Szeto, L.; Mauer, A.M. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan;3(1):59-67.
Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; Rudin, C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-2328.
Hann, C.L.; Rudin, C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park). 2008 Nov 30;22(13):1486-1492; discussion 1493-1486, 1498-1500, 1506.
Marur, S.; Rudin, C.M. Genetic alterations in head and neck squamous cell carcinogenesis. In: Rose, B.D., editor, UpToDate: Oncology. Wellesley, MA: UpToDate; 2008.
Marur, S.; Rudin, C.M. Chemoprevention in oral dysplasia. In: Rose, B.D., editor, UpToDate: Oncology. Wellesley, MA: UpToDate; 2008.
Rudin, C.M.; Hann, C.L.; Peacock, C.D.; Watkins, D.N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):315-322.
Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L.; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E.; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 1;26(7):1119-1127.
Rudin, C.M.; Salgia, R.; Wang, X.; Hodgson, L.D.; Masters, G.A.; Green, M.; Vokes, E.E. A Randomized phase II study of carboplatin and etoposide with or without oblimersen, antisense, bcl-2, for extensive stage small cell lung cancer. J Clin Oncol. 2008 Feb 20;26:870-876.
Daniel, V.C.; Marchionni, L.; Hierman, J.S.; Rhodes, J.T.; Devereux, W.L.; Rudin, C.M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C.D.; Watkins, D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009 Apr 15;69(8):3364-3373.
Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.
Hillion, J.; Wood, L.J.; Mukherjee, M.; Bhattacharya, R.; Di Cello, F.; Kowalski, J.; Elbahloul, O.; Segal, J.; Poirier, J.; Rudin, C.M.; Dhara, S.; Belton, A.; Joseph, B.; Zucker, S.; Resar, L.M. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res. 2009 Nov;7(11):1803-1812.
Hulleman, E.; Kazemier, K.M.; Holleman, A.; VanderWeele, D.J.; Rudin, C.M.; Broekhuis, M.J.; Evans, W.E.; Pieters, R.; Den Boer, M.L. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009 Feb 26;113(9):2014-2021.
Riely, G.J.; Rizvi, N.A.; Kris, M.G.; Milton, D.T.; Solit, D.B.; Rosen, N.; Senturk, E.; Azzoli, C.G.; Brahmer, J.R.; Sirotnak, F.M.; Seshan, V.E.; Fogle, M.; Ginsberg, M.; Miller, V.A.; Rudin, C.M. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jan 10;27(2):264-270.
Rudin, C.; Minna, J. Cancer stem cells. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1079-1081.
Rudin, C.M.; Avila-Tang, E.; Harris, C.C.; Herman, J.G.; Hirsch, F.R.; Pao, W.; Schwartz, A.G.; Vahakangas, K.H.; Samet, J.M. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009 Sep 15;15(18):5646-5661.
Rudin, C.M.; Avila-Tang, E.; Samet, J.M. Lung cancer in never smokers: a call to action. Clin Cancer Res. 2009 Sep 15;15(18):5622-5625.
Rudin, C.M.; Hann, C.L.; Laterra, J.; Yauch, R.L.; Callahan, C.A.; Fu, L.; Holcomb, T.; Stinson, J.; Gould, S.E.; Coleman, B.; LoRusso, P.M.; Von Hoff, D.D.; de Sauvage, F.J.; Low, J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England journal of medicine. 2009 Sep 17;361(12):1173-1178.
Samet, J.M.; Avila-Tang, E.; Boffetta, P.; Hannan, L.M.; Olivo-Marston, S.; Thun, M.J.; Rudin, C.M. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009 Sep 15;15(18):5626-5645.
Schifferli, A.; von Vigier, R.O.; Fontana, M.; Sparta, G.; Schmid, H.; Bianchetti, M.G.; Rudin, C. Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003. European journal of pediatrics. 2009 Oct 15.
Von Hoff, D.D.; LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Yauch, R.L.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Mackey, H.M.; Lum, B.L.; Darbonne, W.C.; Marsters, J.C., Jr.; de Sauvage, F.J.; Low, J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-1172.
Yauch, R.L.; Dijkgraaf, G.J.; Alicke, B.; Januario, T.; Ahn, C.P.; Holcomb, T.; Pujara, K.; Stinson, J.; Callahan, C.A.; Tang, T.; Bazan, J.F.; Kan, Z.; Seshagiri, S.; Hann, C.L.; Gould, S.E.; Low, J.A.; Rudin, C.M.; de Sauvage, F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009 Oct 23;326(5952):572-574.
Burns, T.F.; Rudin, C.M. Lung cancer in 'never-smokers': beyond EGFR mutations and EGFR-TK inhibitors. Oncology (Williston Park). 2010 Jan;24(1):48-49.
Kanarek, N.F.; Tsai, H.L.; Metzger-Gaud, S.; Damron, D.; Guseynova, A.; Klamerus, J.F.; Rudin, C.M. Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010 Dec;8(12):1343-1351.
Klamerus, J.F.; Bruinooge, S.S.; Ye, X.; Klamerus, M.L.; Damron, D.; Lansey, D.; Lowery, J.C.; Diaz, L.A., Jr.; Ford, J.G.; Kanarek, N.; Rudin, C.M. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res. 2010 Dec 15;16(24):5997-6003.
Paik, P.K.; Rudin, C.M.; Brown, A.; Rizvi, N.A.; Takebe, N.; Travis, W.; James, L.; Ginsberg, M.S.; Juergens, R.; Markus, S.; Tyson, L.; Subzwari, S.; Kris, M.G.; Krug, L.M. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-1085.
Paller, C.J.; Rudin, C.M. Youth has no age: cancer treatment for older Americans. Oncology (Williston Park). 2010 Nov 15;24(12):1114, 1118, 1120.
Peacock, C.D.; Rudin, C.M. Skin deep and deeper: multiple pathways in basal cell carcinogenesis. Cancer Prev Res (Phila). 2010 Oct;3(10):1213-1216.
Rudin, C.M. Beyond the scalpel: targeting hedgehog in skin cancer prevention. Cancer Prev Res (Phila). 2010 Jan;3(1):1-3.
Rudin CM, Salgia R, Wang X, Hodgson L, Masters GA, Green M, Vokes EE. (2008) A randomized phase II study of carboplatin and etoposide with or without oblimersen, antisense bcl-2, for extensive stage small cell lung cancer. J Clin Oncol 26:870-6.
Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-2.
Hann CL, Daniel VC, Hierman J, Sugar E, Cope L, Lin M, Watkins DN, Rudin CM. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of Bcl-2, in small cell lung cancer. Cancer Res 68:2321-8.
Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJC, Evans WE, Pieters R, Den Boer ML. (2009) Inhibition of glycolysis modulates prednisolone resistance in pediatric acute lymphoblastic leukemia cells. Blood 113:2014-21.
Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Seshan VE, Fogle M, Ginsberg M, Miller VA, Rudin CM. (2009) Randomized phase 2 study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with stage IIIB or IV non-small cell lung cancer. J Clin Oncol 27:264-70.
Guarino MJ, Schneider CJ, Hosford MA, Brahmer JR, Rudin CM, Finckenstein FG, Philip-Norton RE, Lu H, Weber MR, Ettinger DS. (2009) Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 14:119-20.
Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Dorsch M, Parmigiani G, Peacock C, Watkins DN. (2009) A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69:3364-73.
Rudin CM, Avila-Tang E, Samet JM. (2009) Lung cancer in never smokers: a call to action. Clin Cancer Res 15:5622-25.
Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Thun MJ, Rudin CM. (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15: 5626-45.
Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. (2009) Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 15:5646-611.
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, de Sauvage FJ, Low JA. (2009). Inhibition of the Hedgehog pathway in advanced basal cell carcinoma. New Engl J Med 361:1164-72.
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff D, de Sauvage FJ, Low JA. (2009) Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. New Engl J Med 361:1173-8.
Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan A, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572-4.
Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, di Cello F, Kowalski J, Elbahloul O, Segal J, Poirier J, Rudin CM, Dhara S, Belton A, Joseph B, Zucker S, Resar LM. (2009) Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large cell lung cancer. Mol Cancer Ther 7:1803-12.
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg M, Markus S, Juergens R, Tyson L, Subzwari S, Kris MG, Krug LM. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol; (in press).
Research Interests
- phase 1 trials
- lung cancer
More Info
Languages
- English
Clinical Trials
- Phase 1 trials
- lung cancer
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts